Abstract:Background: The study of high-throughput genomic profiles from a pharmacogenomics viewpoint has provided unprecedented insights into the oncogenic features modulating drug response. A recent study screened for the response of a thousand human cancer cell lines to a wide collection of anti-cancer drugs and illuminated the link between cellular genotypes and vulnerability. However, due to essential differences between cell lines and tumors, to date the translation into predicting drug response in tumors remains challenging. Recently, advances in deep learning have revolutionized bioinformatics and introduced new techniques to the integration of genomic data. Its application on pharmacogenomics may fill the gap between genomics and drug response and improve the prediction of drug response in tumors. Results: We proposed a deep learning model to predict drug response (DeepDR) based on mutation and expression profiles of a cancer cell or a tumor. The model contains three deep neural networks (DNNs), i) a mutation encoder pre-trained using a large pan-cancer dataset (The Cancer Genome Atlas; TCGA) to abstract core representations of high-dimension mutation data, ii) a pre-trained expression encoder, and iii) a drug response predictor network integrating the first two subnetworks. Given a pair of mutation and expression profiles, the model predicts IC50 values of 265 drugs. We trained and tested the model on a dataset of 622 cancer cell lines and achieved an overall prediction performance of mean squared error at 1.96 (log-scale IC50 values). The performance was superior in prediction error or stability than two classical methods (linear regression and support vector machine) and four analog DNN models of DeepDR, including DNNs built without TCGA pre-training, partly replaced by principal components, and built on individual types of input data. We then applied the model to predict drug response of 9059 tumors of 33 cancer types. Using per-cancer and pan-cancer settings, the model predicted both known, including EGFR inhibitors in non-small cell lung cancer and tamoxifen in ER+ breast cancer, and novel drug targets, such as vinorelbine for TTN-mutated tumors. The comprehensive analysis further revealed the molecular mechanisms underlying the resistance to a chemotherapeutic drug docetaxel in a pan-cancer setting and the anti-cancer potential of a novel agent, CX-5461, in treating gliomas and hematopoietic malignancies. Conclusions: Here we present, as far as we know, the first DNN model to translate pharmacogenomics features identified from in vitro drug screening to predict the response of tumors. The results covered both well-studied and novel mechanisms of drug resistance and drug targets. Our model and findings improve the prediction of drug response and the identification of novel therapeutic options.

Predicting Drug Responses by Propagating Interactions through Text-Enhanced Drug-Gene Networks

Improving drug response prediction via integrating gene relationships with deep learning

A Deep Neural Network for Predicting Synergistic Drug Combinations on Cancer

DGDRP: drug-specific gene selection for drug response prediction via re-ranking through propagating and learning biological network

A novel heterogeneous network-based method for drug response prediction in cancer cell lines

A Novel Approach For Drug Response Prediction In Cancer Cell Lines Via Network Representation Learning

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

Transfer learning of condition-specific perturbation in gene interactions improves drug response prediction

drGAT: Attention-Guided Gene Assessment of Drug Response Utilizing a Drug-Cell-Gene Heterogeneous Network

From Gene Expression to Drug Response: A Collaborative Filtering Approach

GPDRP: a multimodal framework for drug response prediction with graph transformer

Learning the Cellular Activity Representation Based on Gene Regulatory Networks for Prediction of Tumor Response to Drugs

Predicting drug synergy using a network propagation inspired machine learning framework

Predicting Rich Drug-Drug Interactions via Biomedical Knowledge Graphs and Text Jointly Embedding

Interpretable Drug Response Prediction through Molecule Structure-aware and Knowledge-Guided Visible Neural Network

Predicting transcriptional responses to novel chemical perturbations using deep generative model for drug discovery

Pathway-Guided Deep Neural Network toward Interpretable and Predictive Modeling of Drug Sensitivity

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Prediction of Synergistic Anti-Cancer Drug Combinations Based on Drug Target Network and Drug Induced Gene Expression Profiles

Predicting drug activity against cancer through genomic profiles and SMILES

TGSA: protein-protein association-based twin graph neural networks for drug response prediction with similarity augmentation